Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Tuesday, September 19, 2017
 
Recommended for you
Drug Stocks Benefit from the Sound of Silence
The Wall Street Journal • Charley Grant
Gilead Sciences prices $3B in debt for Kite Pharma deal
Seeking Alpha • Jason Aycock
Gilead Sciences Portfolio: Performance Update
Seeking Alpha • David Pinsen
Gilead: A Poor Payback Period For Kite Pharma?
Seeking Alpha • Antonio Carradinha
Your Weekly Pharma Scoop: Valeant's CRL Resolution, Eagle Undervalued, Array Positive Results
Seeking Alpha • Avisol Capital Partners
Gilead Sciences' (GILD) CEO John Milligan Presents at Morgan Stanley Global Healthcare Conference - Transcript
Seeking Alpha
The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
MarketWatch • Emma Court
The FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks
Fortune Magazine • Sy Mukherjee
Gilead: This Dividend Gold Mine Is Far From Played Out
Seeking Alpha • Pendragony
AbbVie's drug for all types of hepatitis C wins EU approval
Reuters
 
Recommended for You
Biotechnology, Finance
Drug Stocks Benefit from the Sound of Silence
The Wall Street JournalCharley Grant
Peace and quiet never sounded so good to drug stock investors. The NYSE Arca Pharmaceutical Index is up 5% over the last month, which has handily outpaced the broader market. The Nasdaq Biotechnology Index, meanwhile, has shot up 8% over that same...
Share
Biotechnology, Gilead Sciences
Gilead Sciences prices $3B in debt for Kite Pharma deal
Seeking AlphaJason Aycock
Gilead Sciences (GILD -1.7%) has priced $3B of senior unsecured debt, in four tranches, to help fund its $11.9B acquisition of Kite Pharma (NASDAQ:KITE). The company priced $750M in floating-rate notes, maturing September 2018; $750M in floating-rate notes maturing March 2019; $500M...
Share
Finance, Gilead Sciences
Gilead Sciences Portfolio: Performance Update
Seeking AlphaDavid Pinsen
Summary With Gilead a subject of renewed discussion since its Kite Pharma acquisition, we update the performance from our Gilead hedged portfolio from early May. So far, it has more than doubled the performance of the market, though it has lagged an...
Share
Cancer, Economic Policy
Gilead: A Poor Payback Period For Kite Pharma?
Seeking AlphaAntonio Carradinha
Summary Gilead Sciences must focus on the development of new products. Kite Pharma seems to have been bought at a fairly expensive price ($180 a share). A P/E of ~10 is still a high number if we compare it with the company's...
Share
Gilead Sciences, Pfizer, Inc.
Your Weekly Pharma Scoop: Valeant's CRL Resolution, Eagle Undervalued, Array Positive Results
Seeking AlphaAvisol Capital Partners
Summary This is the once-weekly Pharma scoop published by the Total Pharma Tracker. In today's analysis, Valeant's CRL issue may be resolved soon. Array Biopharma showed positive results in phase 3 trials. Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok...
Share
Gilead Sciences, Health Finance
Gilead Sciences' (GILD) CEO John Milligan Presents at Morgan Stanley Global Healthcare Conference - Transcript
Seeking Alpha
Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley Global Healthcare Conference September 11, 2017 09:55 AM ET Executives John F. Milligan - President and CEO Robin L. Washington - EVP and CFO Alessandro Riva - SVP, Hematology and Oncology Therapeutic Area Head Analysts Matthew...
Share
Finance, Gilead Sciences
The Ratings Game: AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
MarketWatchEmma Court
Lions Gate/Courtesy Everett Collection AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks. It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week course of treatment. That’s on paper,...
Share
Gilead Sciences, Health Care Industry
The FDA Just Approved the First Drug That Can Treat All Hepatitis C Strains in Just 8 Weeks
Fortune MagazineSy Mukherjee
The Food and Drug Administration (FDA) approved the first-ever drug that can treat all six major strains of hepatitis C (or HCV) in just eight weeks on Thursday. The approval of AbbVie's Mavyret is bad news for competitors like biotech giant Gilead,...
Share
Gilead Sciences, Health Finance
Gilead: This Dividend Gold Mine Is Far From Played Out
Seeking AlphaPendragony
Summary GILD has been hurt by what should have been predictable declines in the HCV segment. Q2 was a very good quarter, with a beat on both revenue and earnings and a raise in guidance of the rest of 2017. GILD is...
Share
Education, Energy & Utilities
AbbVie's drug for all types of hepatitis C wins EU approval
Reuters
(Reuters) - AbbVie Inc said on Friday it had received European approval to market its drug for treatment of all six major forms of hepatitis C.
Share